Skip to main content
Neumous logo

Neumous

Seoul, South KoreaSee on the mapFounded 2022

  • Focused ultrasound

Neumous is a medical technology company developing a non-invasive focused ultrasound platform for treating neurological disorders. Its technology is designed to temporarily open the blood-brain barrier for targeted delivery of therapeutics and to support precise neuromodulation, with clinical development underway for brain diseases.

Raised
$7M
Investors
10
Founded
2022
Employees
11–50

reccy insights

Recent highlights

Neumous, founded in 2022 and based in Seoul, is developing a therapeutic ultrasound platform intended to temporarily open the blood-brain barrier and support targeted delivery of treatments to the brain. Its stated approach combines focused ultrasound with systemically administered microbubbles, neuronavigation for targeting, and real-time acoustic monitoring. The company describes potential applications in brain diseases, including brain tumors and Alzheimer’s, and its platform also includes focused-ultrasound neuromodulation. Structured company information lists $7.01 million in total funding and identifies a Series A as the latest financing type, but provides no financing date or named investors. As a result, the clearest verifiable milestones are the company’s 2022 founding and its reported Series A financing, while the timing and clinical status of individual programs remain unclear.

Written by reccy's AI from company sites, press and funding records · updated Nov 2026

What makes Neumous distinct

  1. 01Uses focused ultrasound and systemically administered microbubbles to enable temporary, localized blood-brain barrier opening without surgery.
  2. 02Combines neuronavigation with real-time acoustic monitoring to guide and monitor treatment delivery.
  3. 03Designed to support targeted delivery of a broad range of therapeutic modalities to the brain.
  4. 04Develops its platform through clinical work and collaborations with pharmaceutical companies, hospitals, academic institutions, and research partners.

Technology & products

  • Focused ultrasound platform

    A non-invasive therapeutic ultrasound platform designed to temporarily open the blood-brain barrier for targeted delivery of therapeutic agents, with focused-ultrasound neuromodulation also described.

  • Focused ultrasound-mediated blood-brain barrier opening platform
  • Targeted brain drug delivery using focused ultrasound and microbubbles
  • Neuronavigation system for precise ultrasound targeting
  • Real-time acoustic monitoring of microbubble activity
  • Focused ultrasound neuromodulation

Funding

$7M disclosed
10 investors

Investors4

Also backed by
  • Aju IB Investment
  • KIMCo Foundation
  • SL Investment Co., Ltd.

Similar companies

About Neumous

Products
Focused ultrasound platform
Focus areas
Medical devices, focused ultrasound, blood-brain barrier, drug delivery, neurology, neuroscience, therapeutics, clinical research
Headquarters
Seoul, South Korea
Founded
2022
Employees
11–50
Status
Active · private